UY33998A - Moléculas de unión biespecíficas que se unen a vegf y ang2 - Google Patents

Moléculas de unión biespecíficas que se unen a vegf y ang2

Info

Publication number
UY33998A
UY33998A UY0001033998A UY33998A UY33998A UY 33998 A UY33998 A UY 33998A UY 0001033998 A UY0001033998 A UY 0001033998A UY 33998 A UY33998 A UY 33998A UY 33998 A UY33998 A UY 33998A
Authority
UY
Uruguay
Prior art keywords
ang2
vegf
bispecific
join
molecules
Prior art date
Application number
UY0001033998A
Other languages
English (en)
Inventor
Gschwind Andreas
Boucneau Joachim
Marie-Ange Buyse
Depla Erik
Rene Georg Ott
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45895502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33998(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY33998A publication Critical patent/UY33998A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Se describen moléculas de unión biespecíficas que se unen tanto a VEGF como a Ang2, preferiblemente en forma de dominios variables individuales de inmunoglobulina tales como VHH y anticuerpos de dominio, composiciones farmacéuticas que las contienen y su uso en el tratamiento de enfermedades que están asociadas con los efectos mediados por VEGF y/o Ang2 sobre la angiogénesis. Además, también se describen ácidos nucleicos que codifican moléculas de unión biespecíficas, células hospedadoras y métodos para prepararlos.
UY0001033998A 2011-04-01 2012-03-30 Moléculas de unión biespecíficas que se unen a vegf y ang2 UY33998A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11160921 2011-04-01

Publications (1)

Publication Number Publication Date
UY33998A true UY33998A (es) 2012-09-28

Family

ID=45895502

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033998A UY33998A (es) 2011-04-01 2012-03-30 Moléculas de unión biespecíficas que se unen a vegf y ang2

Country Status (35)

Country Link
US (4) US9527925B2 (es)
EP (2) EP2694546B1 (es)
JP (2) JP6023786B2 (es)
KR (1) KR101907572B1 (es)
CN (2) CN105820243A (es)
AP (1) AP2013007085A0 (es)
AR (1) AR085984A1 (es)
AU (2) AU2012237234B2 (es)
BR (1) BR112013025304B1 (es)
CA (1) CA2827817C (es)
CL (1) CL2013002623A1 (es)
CO (1) CO6801639A2 (es)
CY (1) CY1118339T1 (es)
DK (1) DK2694546T3 (es)
EA (2) EA036746B1 (es)
EC (1) ECSP13013001A (es)
ES (1) ES2606302T3 (es)
HK (2) HK1225400A1 (es)
HR (1) HRP20161689T1 (es)
HU (1) HUE030148T2 (es)
IL (1) IL227936B (es)
LT (1) LT2694546T (es)
MA (1) MA34979B1 (es)
MX (2) MX343440B (es)
MY (1) MY171007A (es)
PE (1) PE20140448A1 (es)
PL (1) PL2694546T3 (es)
PT (1) PT2694546T (es)
RS (1) RS55361B1 (es)
SG (2) SG193561A1 (es)
SI (1) SI2694546T1 (es)
TN (1) TN2013000390A1 (es)
UA (1) UA114707C2 (es)
UY (1) UY33998A (es)
WO (1) WO2012131078A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
DK2831111T3 (en) * 2012-03-30 2019-04-29 Boehringer Ingelheim Int Ang2-binding molecules
JP6154900B2 (ja) 2012-07-13 2017-06-28 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
CN104661679A (zh) * 2012-09-28 2015-05-27 勃林格殷格翰国际有限公司 包含双重血管生成素-2/Dll4结合物和抗VEGF药剂的药物组合
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
US20170152323A1 (en) * 2015-01-16 2017-06-01 Immunwork Inc. Anti-inflammatory molecules with tissue-targeting functions
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
CA2981103A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
AU2016239948B2 (en) 2015-03-31 2022-03-17 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2017020001A2 (en) * 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2
AU2016307943A1 (en) * 2015-08-14 2018-02-15 Allergan, Inc. Heavy chain only antibodies to PDGF
TWI748962B (zh) * 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
WO2017080850A1 (en) * 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
SI3383425T1 (sl) 2015-12-04 2020-11-30 Boehringer Ingelheim International Gmbh Biparatopični polipeptidi, ki antagonizirajo WNT-signaliziranje v tumorskih celicah
WO2018037001A1 (en) 2016-08-23 2018-03-01 Medimmune Limited Anti-vegf-a antibodies and uses thereof
KR102543878B1 (ko) 2016-08-23 2023-06-14 메디뮨 리미티드 항-ｖｅｇｆ-ａ 및 항-ａｎｇ2 항체 및 이의 용도
CN116869457A (zh) * 2016-12-14 2023-10-13 比奥拉治疗股份有限公司 使用jak抑制剂治疗胃肠道疾病及装置
RU2648164C1 (ru) * 2016-12-19 2018-03-22 Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
MY200744A (en) 2017-05-31 2024-01-13 Boehringer Ingelheim Int Gmbh Polypeptides antagonizing wnt signaling in tumor cells
KR20200013231A (ko) * 2017-06-02 2020-02-06 베링거 인겔하임 인터내셔날 게엠베하 항암 조합 요법
IL276383B2 (en) 2018-02-06 2024-01-01 Hoffmann La Roche Treatment of ophthalmological diseases
US20220257600A1 (en) * 2018-06-20 2022-08-18 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
BR112020026862A2 (pt) 2018-06-29 2021-04-20 Gensun Biopharma, Inc. antagonistas antitumorais de reguladores de pontos de verificação imunológica
PE20211865A1 (es) 2018-10-29 2021-09-21 Hoffmann La Roche Formulacion de anticuerpos
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
CN115916816A (zh) * 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗血清白蛋白抗体
WO2021155151A1 (en) * 2020-01-29 2021-08-05 The Methodist Hospital System Multivalent ligands targeting cell surface receptors and force measurement platform for making the same
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
CA3189030A1 (en) 2020-07-07 2022-01-13 Kanaph Therapeutics Inc. Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof
JP2023550591A (ja) 2020-11-02 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体
EP4019548A1 (en) * 2020-12-23 2022-06-29 Vrije Universiteit Brussel Anti lag3 vhhs and their use
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
CA3221192A1 (en) 2021-06-04 2022-12-08 Innovent Biologics (Suzhou) Co. Ltd. Bispecific binding molecule binding to vegf and ang2 and use thereof
AU2022327397A1 (en) * 2021-08-13 2024-03-14 Innovent Biologics (Suzhou) Co., Ltd. Anti-vegf a and -vegf c bispecific antibody and use thereof
KR20240048555A (ko) * 2021-09-10 2024-04-15 소테르 바이오파마 피티이. 리미티드 항 ang2 항체 및 그 제조방법과 응용
CU20210101A7 (es) * 2021-12-15 2023-07-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen a factores de crecimiento proangiogénicos
WO2024055996A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa抗体或其抗原结合片段及其应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
US5408535A (en) 1993-09-07 1995-04-18 Miles Inc. Video test strip reader and method for evaluating test strips
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002056910A1 (en) 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2003074670A2 (en) 2002-03-01 2003-09-12 Ball Horticultural Company Lis promoter for expression of transgenes in floral tissues
WO2004024764A1 (en) 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
US20050043220A1 (en) 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
PL1639011T3 (pl) 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
EP2281885A1 (en) 2003-08-27 2011-02-09 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
DK1687338T3 (da) 2003-11-07 2011-02-07 Ablynx Nv Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
PE20061075A1 (es) 2004-12-17 2006-11-15 Genentech Inc Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
PL3415535T3 (pl) 2005-05-20 2021-06-14 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
US8377398B2 (en) 2005-05-31 2013-02-19 The Board Of Regents Of The University Of Texas System Methods and compositions related to determination and use of white blood cell counts
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2621226A1 (en) 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
WO2007043109A1 (ja) 2005-09-30 2007-04-19 Fujitsu Limited 情報記憶装置
WO2007068895A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
JP5489465B2 (ja) 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
EA200801515A1 (ru) 2006-01-24 2009-02-27 Домантис Лимитед Лиганды, которые связывают il-4 и/или il-13
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US7570881B2 (en) 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
NZ572177A (en) 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
KR20090016762A (ko) 2006-06-06 2009-02-17 제넨테크, 인크. 혈관 발달을 조정하기 위한 조성물 및 방법
ME00591A (en) 2006-08-07 2011-12-20 Use of dii4 antagonists in ishemic injury or vascular insufficiency
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
JP2010502208A (ja) * 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． 半減期の長い血清アルブミン結合タンパク質
ATE536369T1 (de) 2006-10-11 2011-12-15 Ablynx Nv Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
JP2010507594A (ja) 2006-10-20 2010-03-11 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2121757A2 (en) 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
WO2008119353A1 (en) * 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
MX2009012968A (es) 2007-06-06 2010-04-01 Domantis Ltd Polipeptidos, dominios variables de anticuerpo y antagonistas.
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2212432A4 (en) 2007-10-22 2011-10-19 Schering Corp COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
PL2215121T3 (pl) 2007-11-26 2016-07-29 Bayer Ip Gmbh Przeciwciała przeciwko mezotelinie i ich zastosowania
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
CA3020290A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
JP5796831B2 (ja) 2008-09-03 2015-10-21 ジェネンテック， インコーポレイテッド 多重特異性抗体
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP5823871B2 (ja) 2008-12-10 2015-11-25 アブリンクス エン．ヴェー． 血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン／Ｔｉｅシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
EP2387721A4 (en) 2009-01-13 2014-05-14 Fio Corp PORTABLE DIAGNOSTIC TEST DEVICE AND METHOD FOR USE WITH AN ELECTRONIC DEVICE AND TEST CARTRIDGE FOR QUICK DIAGNOSTIC TESTS
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
EP2443150B1 (en) 2009-06-17 2015-01-21 AbbVie Biotherapeutics Inc. Anti-vegf antibodies and their uses
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
EP3064509A3 (en) 2010-02-23 2016-11-02 F. Hoffmann-La Roche AG Anti-angiogenesis therapy for the treatment of ovarian cancer
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012012499A1 (en) 2010-07-20 2012-01-26 Nurx Pharmaceuticals, Inc. Optical reader system
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
CN103492583A (zh) 2010-11-02 2014-01-01 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20140114208A1 (en) 2011-05-27 2014-04-24 Novartis Ag Method of treating vision disorders
HUE042192T2 (hu) 2011-09-23 2019-06-28 Oncomed Pharm Inc VEGF/DLL4-kötõ ágensek és alkalmazásaik
DK2831111T3 (en) * 2012-03-30 2019-04-29 Boehringer Ingelheim Int Ang2-binding molecules
US9292583B2 (en) * 2012-11-27 2016-03-22 Google Inc. Method of displaying search results

Also Published As

Publication number Publication date
UA114707C2 (uk) 2017-07-25
CN103562222B (zh) 2016-04-06
HUE030148T2 (en) 2017-04-28
KR20140018317A (ko) 2014-02-12
CL2013002623A1 (es) 2014-02-14
US10414828B2 (en) 2019-09-17
AU2012237234A1 (en) 2013-09-05
ECSP13013001A (es) 2013-12-31
JP6297657B2 (ja) 2018-03-20
AU2017200237B2 (en) 2018-05-17
CN105820243A (zh) 2016-08-03
CN103562222A (zh) 2014-02-05
MX337543B (es) 2016-03-10
EA201600338A1 (ru) 2016-09-30
ES2606302T3 (es) 2017-03-23
MX343440B (es) 2016-11-07
AP2013007085A0 (en) 2013-08-31
EA025148B1 (ru) 2016-11-30
BR112013025304B1 (pt) 2022-10-11
JP2014515602A (ja) 2014-07-03
US20170247475A1 (en) 2017-08-31
MY171007A (en) 2019-09-23
SG10201602373TA (en) 2016-05-30
CY1118339T1 (el) 2017-06-28
HK1190412A1 (zh) 2014-07-04
KR101907572B1 (ko) 2018-10-15
SG193561A1 (en) 2013-11-29
MX2013010949A (es) 2014-06-06
PL2694546T3 (pl) 2017-03-31
PE20140448A1 (es) 2014-04-13
AR085984A1 (es) 2013-11-13
DK2694546T3 (en) 2016-12-05
WO2012131078A1 (en) 2012-10-04
EP3144322A3 (en) 2017-05-31
EA201301108A1 (ru) 2014-03-31
HRP20161689T1 (hr) 2017-02-24
CA2827817A1 (en) 2012-10-04
LT2694546T (lt) 2016-11-10
AU2017200237A1 (en) 2017-02-02
PT2694546T (pt) 2016-12-28
CA2827817C (en) 2020-12-15
US11161916B2 (en) 2021-11-02
JP2017023152A (ja) 2017-02-02
MA34979B1 (fr) 2014-03-01
TN2013000390A1 (en) 2015-01-20
US9527925B2 (en) 2016-12-27
SI2694546T1 (sl) 2017-01-31
EA036746B1 (ru) 2020-12-16
NZ614249A (en) 2015-05-29
JP6023786B2 (ja) 2016-11-09
RS55361B1 (sr) 2017-03-31
US20200010569A1 (en) 2020-01-09
EP2694546B1 (en) 2016-09-21
HK1225400A1 (zh) 2017-09-08
EP3144322A2 (en) 2017-03-22
IL227936B (en) 2018-06-28
AU2012237234B2 (en) 2016-10-20
CO6801639A2 (es) 2013-11-29
US20220017642A1 (en) 2022-01-20
US20130078248A1 (en) 2013-03-28
BR112013025304A2 (pt) 2017-06-06
IL227936A0 (en) 2013-09-30
EP2694546A1 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
ECSP13013001A (es) Moléculas de unión biespecíficas que se unen a vegf y ang2.
ECSP12011835A (es) Moléculas de unión biespecíficas para la terapia anti-angiogénesis.
UY33588A (es) Moleculas de union a vegf
ECSP13012996A (es) Moléculas de unión biespecíficas que se unen a dll4 y ang2.
CY1122007T1 (el) Μορια δεσμευσης-ang2
ECSP12011828A (es) Moléculas de unión a dll-4.
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
UY36974A (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
CL2015001507A1 (es) Proteínas de unión al antígeno bcma
EA201791485A1 (ru) Анти-cd47-антитела и их применения
AR091024A1 (es) Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos
EA201400579A1 (ru) Антитела к il-36r
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
EA201492101A1 (ru) Антитела против fcrn
CR20130359A (es) Anticuerpos del cea
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
AR089528A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
EA201401204A1 (ru) Антитела к il-23p19
CR20150259A (es) Anticuerpos egfr/c-met biespecíficos
BR112014024275A2 (pt) "aptâmeros para pdgf e vegf, construtos de aptâmeros e seus usos"